Search

Roivant Sciences Ltd

Lezárt

SzektorEgészségügy

36.47 0.3

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

35.65

Maximum

36.56

Fő mutatók

By Trading Economics

Bevétel

-646M

-291M

Értékesítés

-1.1M

1.4M

Egy részvényre jutó nyereség

-0.45

Profit margin

-20,152.982

Munkavállalók

721

EBITDA

-743M

-288M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+16.39% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

2.1B

26B

Előző nyitás

36.17

Előző zárás

36.47

Hangulat hírek alapján

By Acuity

50%

50%

150 / 340 Rangsor szerint Healthcare

Roivant Sciences Ltd Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

2026. aug. 21. 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

2026. aug. 20. 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

2026. aug. 19. 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

2026. aug. 18. 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

2026. aug. 17. 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

2026. aug. 14. 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

2026. aug. 13. 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

2026. aug. 12. 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

2026. aug. 11. 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

2026. aug. 10. 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

2026. aug. 7. 20:02 UTC

Event
News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

2026. aug. 6. 20:03 UTC

News
Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

2026. aug. 5. 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

2026. aug. 4. 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

2026. aug. 3. 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

2026. júl. 31. 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

2026. júl. 30. 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

2026. júl. 29. 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

2026. júl. 28. 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

2026. júl. 24. 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

2026. júl. 23. 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

2026. júl. 22. 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

2026. júl. 21. 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

2026. júl. 20. 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Társak összehasonlítása

Árváltozás

Roivant Sciences Ltd Előrejelzés

Célár

By TipRanks

16.39% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 42.25 USD  16.39%

Magas 50 USD

Alacsony 37 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Roivant Sciences Ltd termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

7

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat